8771 related articles for article (PubMed ID: 33629336)
1. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
[TBL] [Abstract][Full Text] [Related]
2. COVID-19 Vaccination Reactogenicity in Persons With Multiple Sclerosis.
Briggs FBS; Mateen FJ; Schmidt H; Currie KM; Siefers HM; Crouthamel S; Bebo BF; Fiol J; Racke MK; O'Connor KC; Kolaczkowski LG; Klein P; Loud S; McBurney RN
Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34753828
[TBL] [Abstract][Full Text] [Related]
3. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021.
Rosenblum HG; Hadler SC; Moulia D; Shimabukuro TT; Su JR; Tepper NK; Ess KC; Woo EJ; Mba-Jonas A; Alimchandani M; Nair N; Klein NP; Hanson KE; Markowitz LE; Wharton M; McNally VV; Romero JR; Talbot HK; Lee GM; Daley MF; Mbaeyi SA; Oliver SE
MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(32):1094-1099. PubMed ID: 34383735
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.
Nanduri S; Pilishvili T; Derado G; Soe MM; Dollard P; Wu H; Li Q; Bagchi S; Dubendris H; Link-Gelles R; Jernigan JA; Budnitz D; Bell J; Benin A; Shang N; Edwards JR; Verani JR; Schrag SJ
MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1163-1166. PubMed ID: 34437519
[TBL] [Abstract][Full Text] [Related]
5. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine - United States, December 14-23, 2020.
;
MMWR Morb Mortal Wkly Rep; 2021 Jan; 70(2):46-51. PubMed ID: 33444297
[TBL] [Abstract][Full Text] [Related]
6. Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans - Five Veterans Affairs Medical Centers, United States, February 1-September 30, 2021.
Bajema KL; Dahl RM; Evener SL; Prill MM; Rodriguez-Barradas MC; Marconi VC; Beenhouwer DO; Holodniy M; Lucero-Obusan C; Brown ST; Tremarelli M; Epperson M; Mills L; Park SH; Rivera-Dominguez G; Morones RG; Ahmadi-Izadi G; Deovic R; Mendoza C; Jeong C; Schrag SJ; Meites E; Hall AJ; Kobayashi M; McMorrow M; Verani JR; Thornburg NJ; Surie D; ; ;
MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(49):1700-1705. PubMed ID: 34882654
[TBL] [Abstract][Full Text] [Related]
7. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
Amanpour S
Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
[TBL] [Abstract][Full Text] [Related]
8. Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March-August 2021.
Self WH; Tenforde MW; Rhoads JP; Gaglani M; Ginde AA; Douin DJ; Olson SM; Talbot HK; Casey JD; Mohr NM; Zepeski A; McNeal T; Ghamande S; Gibbs KW; Files DC; Hager DN; Shehu A; Prekker ME; Erickson HL; Gong MN; Mohamed A; Henning DJ; Steingrub JS; Peltan ID; Brown SM; Martin ET; Monto AS; Khan A; Hough CL; Busse LW; Ten Lohuis CC; Duggal A; Wilson JG; Gordon AJ; Qadir N; Chang SY; Mallow C; Rivas C; Babcock HM; Kwon JH; Exline MC; Halasa N; Chappell JD; Lauring AS; Grijalva CG; Rice TW; Jones ID; Stubblefield WB; Baughman A; Womack KN; Lindsell CJ; Hart KW; Zhu Y; Mills L; Lester SN; Stumpf MM; Naioti EA; Kobayashi M; Verani JR; Thornburg NJ; Patel MM;
MMWR Morb Mortal Wkly Rep; 2021 Sep; 70(38):1337-1343. PubMed ID: 34555004
[TBL] [Abstract][Full Text] [Related]
9. Interim Recommendations of the Advisory Committee on Immunization Practices for Use of Moderna and Pfizer-BioNTech COVID-19 Vaccines in Children Aged 6 Months-5 Years - United States, June 2022.
Fleming-Dutra KE; Wallace M; Moulia DL; Twentyman E; Roper LE; Hall E; Link-Gelles R; Godfrey M; Woodworth KR; Anderson TC; Rubis AB; Shanley E; Jones JM; Morgan RL; Brooks O; Talbot HK; Lee GM; Bell BP; Daley M; Meyer S; Oliver SE
MMWR Morb Mortal Wkly Rep; 2022 Jul; 71(26):859-868. PubMed ID: 35771731
[TBL] [Abstract][Full Text] [Related]
10. Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices - United States, June 2021.
Gargano JW; Wallace M; Hadler SC; Langley G; Su JR; Oster ME; Broder KR; Gee J; Weintraub E; Shimabukuro T; Scobie HM; Moulia D; Markowitz LE; Wharton M; McNally VV; Romero JR; Talbot HK; Lee GM; Daley MF; Oliver SE
MMWR Morb Mortal Wkly Rep; 2021 Jul; 70(27):977-982. PubMed ID: 34237049
[TBL] [Abstract][Full Text] [Related]
11. COVID-19 mRNA vaccines (Pfizer-BioNTech and Moderna) in patients with multiple sclerosis: a statement by a working group convened by the Section of Multiple Sclerosis and Neuroimmunology of the Polish Neurological Society.
Nojszewska M; Kalinowska A; Adamczyk-Sowa M; KuĊakowska A; Bartosik-Psujek H
Neurol Neurochir Pol; 2021; 55(1):8-11. PubMed ID: 33555604
[TBL] [Abstract][Full Text] [Related]
12. Adverse Effects of Pfizer (BioNTech), Oxford-AstraZeneca (ChAdOx1 CoV-19), and Moderna COVID-19 Vaccines among the Adult Population in Saudi Arabia: A Cross-Sectional Study.
Aldali J; Meo SA; Al-Khlaiwi T
Vaccines (Basel); 2023 Jan; 11(2):. PubMed ID: 36851109
[TBL] [Abstract][Full Text] [Related]
13. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.
Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883
[TBL] [Abstract][Full Text] [Related]
14. The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine - United States, December 2020.
Oliver SE; Gargano JW; Marin M; Wallace M; Curran KG; Chamberland M; McClung N; Campos-Outcalt D; Morgan RL; Mbaeyi S; Romero JR; Talbot HK; Lee GM; Bell BP; Dooling K
MMWR Morb Mortal Wkly Rep; 2020 Dec; 69(50):1922-1924. PubMed ID: 33332292
[TBL] [Abstract][Full Text] [Related]
15. Can mRNA Vaccines Turn the Tables During the COVID-19 Pandemic? Current Status and Challenges.
Sagili Anthony DP; Sivakumar K; Venugopal P; Sriram DK; George M
Clin Drug Investig; 2021 Jun; 41(6):499-509. PubMed ID: 33754328
[TBL] [Abstract][Full Text] [Related]
16. COVID-19 Vaccine Second-Dose Completion and Interval Between First and Second Doses Among Vaccinated Persons - United States, December 14, 2020-February 14, 2021.
Kriss JL; Reynolds LE; Wang A; Stokley S; Cole MM; Harris LQ; Shaw LK; Black CL; Singleton JA; Fitter DL; Rose DA; Ritchey MD; Toblin RL;
MMWR Morb Mortal Wkly Rep; 2021 Mar; 70(11):389-395. PubMed ID: 33735162
[TBL] [Abstract][Full Text] [Related]
17. Finally, an FDA Approval for an Immunization Against COVID-19: Hope on the Horizon.
Powell J; Piszczatoski CR
Ann Pharmacother; 2022 Sep; 56(9):1058-1064. PubMed ID: 35012364
[TBL] [Abstract][Full Text] [Related]
18. Side effects of Pfizer/BioNTech (BNT162b2) COVID-19 vaccine reported by the Birzeit University community.
Abukhalil AD; Shatat SS; Abushehadeh RR; Al-Shami N; Naseef HA; Rabba A
BMC Infect Dis; 2023 Jan; 23(1):5. PubMed ID: 36604613
[TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2: Unique Challenges of the Virus and Vaccines.
Mahmoodpoor A; Sanaie S; Samadi P; Yousefi M; Nader ND
Immunol Invest; 2021 Oct; 50(7):802-809. PubMed ID: 34109900
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
